Kymera Therapeutics

Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021 Oncology degrader programs KT-413 and KT-333 expected to enter clinical development in 2H 2021 WATERTOWN, Mass., May 06, 2021 (GLOBE NEWSWIRE) — Kymera